Caribou Biosciences, Inc. (CRBU)
1.305
0.00 (0.00%)
USD |
NASDAQ |
Sep 21, 16:00
1.305
0.00 (0.00%)
After-Hours: 20:00
Caribou Biosciences Enterprise Value : 52.14M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 52.14M |
| September 17, 2026 | 53.20M |
| September 16, 2026 | 46.84M |
| September 15, 2026 | 48.96M |
| September 14, 2026 | 51.08M |
| September 11, 2026 | 48.96M |
| September 10, 2026 | 59.56M |
| September 09, 2026 | 66.97M |
| September 08, 2026 | 77.57M |
| September 04, 2026 | 80.75M |
| September 03, 2026 | 80.75M |
| September 02, 2026 | 83.93M |
| September 01, 2026 | 78.63M |
| August 31, 2026 | 77.57M |
| August 28, 2026 | 86.05M |
| August 27, 2026 | 90.29M |
| August 26, 2026 | 89.23M |
| August 25, 2026 | 100.89M |
| August 24, 2026 | 88.17M |
| August 21, 2026 | 90.29M |
| August 20, 2026 | 84.99M |
| August 19, 2026 | 88.17M |
| August 18, 2026 | 79.69M |
| August 17, 2026 | 80.75M |
| August 14, 2026 | 81.81M |
| Date | Value |
|---|---|
| August 13, 2026 | 84.99M |
| August 12, 2026 | 94.53M |
| August 11, 2026 | 93.47M |
| August 10, 2026 | 90.29M |
| August 07, 2026 | 89.23M |
| August 06, 2026 | 88.17M |
| August 05, 2026 | 84.99M |
| August 04, 2026 | 80.75M |
| August 03, 2026 | 73.33M |
| July 31, 2026 | 69.09M |
| July 30, 2026 | 74.39M |
| July 29, 2026 | 70.15M |
| July 28, 2026 | 72.27M |
| July 27, 2026 | 82.87M |
| July 24, 2026 | 80.75M |
| July 23, 2026 | 87.11M |
| July 22, 2026 | 90.29M |
| July 21, 2026 | 89.23M |
| July 20, 2026 | 86.05M |
| July 17, 2026 | 89.23M |
| July 16, 2026 | 90.29M |
| July 15, 2026 | 97.71M |
| July 14, 2026 | 99.83M |
| July 13, 2026 | 105.13M |
| July 10, 2026 | 118.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.335B |
| Vir Biotechnology, Inc. | 1.352B |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.28M |
| Revenue (Quarterly) | 1.499M |
| Total Expenses (Quarterly) | 25.78M |
| EPS Diluted (Quarterly) | -0.2404 |
| Gross Profit Margin (Quarterly) | 58.31% |
| Profit Margin (Quarterly) | -1.62K% |
| Earnings Yield | -82.57% |
| Normalized Earnings Yield | -82.57 |